Abstract: Antibiotic Bu-2659 complex, containing components A, B, C, D and E, is produced by cultivation of Streptomyces hygroscopicus Strain No. J296-21, ATCC No. 39150.
Abstract: Disclosed are novel plasmids which can replicate autonomously in microorganisms belonging to the genus Corynebacterium or Brevibacterium and which carry a gene for resistance to streptomycin and/or spectinomycin. The plasmids are useful as a cloning vector.
Abstract: A process for bacterially producing heterologous polypeptides, particularly those such as human IFN-.beta. that inhibit bacterial growth, in which bacteria that have been transformed to express the heterologous polypeptide under the control of a trp promoter-operator are cultivated in a known volume of medium containing an excess of a preferred carbon source such as glucose and a predetermined amount of tryptophan that corresponds approximately to the amount of tryptophan contained in the bacteria in the volume of medium at a predetermined elevated cellular density, whereby expression of the heterologous polypeptide is substantially repressed until the bacteria grow to approximately the predetermined elevated cellular density and is thereafter automatically derepressed to permit expression of the heterologous polypeptide.
Abstract: Gene products of plasmid DNA, such as proteins, are prepared in high yields by cultivating bacteria carrying a plasmid which shows a controlled constant plasmid copy number at one temperature and a much higher or totally uncontrolled copy number at a different temperature. The plasmid may be prepared by recombinant DNA technique using a cloning vector showing the temperature dependent plasmid copy number pattern.
Type:
Grant
Filed:
December 8, 1980
Date of Patent:
February 12, 1985
Assignee:
A/S Alfred Benzon
Inventors:
Bernt E. Uhlin, Kurt Nordstrom, Soeren Molin
Abstract: Gene products of plasmid DNA, such as proteins, are prepared in high yields by cultivating bacteria carrying a plasmid which shows a controlled constant plasmid copy number at one temperture and a much higher or totally uncontrolled copy number at a different temperature. The plasmid may be prepared by recombinant DNA technique using a cloning vector showing the temperature dependent plasmid copy number pattern.
Type:
Grant
Filed:
May 22, 1978
Date of Patent:
January 22, 1985
Assignee:
A/S Alfred Benzon
Inventors:
Bernt E. Uhlin, Kurt Nordstrom, Soeren Molin
Abstract: A biologically pure culture of the microorganism Streptomyces pulveraceus subspecies fostreus ATCC 31906 is provided. Strain 31906 is capable of producing the CL 1565 antibiotic complex in a recoverable quantity upon cultivation in an aqueous nutrient medium containing assimilable sources of nitrogen and carbon. The CL 1565 antibiotic complex includes CL 1565-A, -B and -T sodium salt compounds that in dosage form are useful antibiotics and antitumor agents.
Type:
Grant
Filed:
May 25, 1983
Date of Patent:
January 22, 1985
Assignee:
Warner-Lambert Company
Inventors:
Josefino B. Tunac, William E. Dobson, Blanche D. Graham
Abstract: Gene products of plasmid DNA, such as proteins, are prepared in high yields by cultivating bacteria carrying a plasmid which shows a controlled constant plasmid copy number at one temperature and a much higher or totally uncontrolled copy number at a different temperature. The plasmid may be prepared by recombinant DNA technique using a cloning vector showing the temperature dependent plasmid copy number pattern.
Type:
Grant
Filed:
December 8, 1980
Date of Patent:
December 11, 1984
Assignee:
A/S Alfred Benzon
Inventors:
Bernt E. Uhlin, Kurt Nordstr/o/ m, Soeren Molin, Petter Gustaffson
Abstract: Chimeric plasmids capable of transforming bacteria and yeast are described. The plasmids carry the Cm (chloramphenicol resistance) gene and the Tc (tetracycline resistance) gene as selectable markers. The Cm gene allows the plasmids to be selected for in wild-type strains of the yeast Saccharomyces cerevisiae. The Tc gene allows heterologous genes cloned into the plasmids to be selected for in Escherichia coli bacteria.
Abstract: Novel antibiotic U-64,864 producible in a fermentation under controlled conditions using a biologically pure culture of the microorganism Streptomyces braegensis Dietz sp.n., NRRL 12567. This antibiotic is active against various Gram-positive bacteria, for example, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus pneumoniae. Thus, antibiotic U-64,864 can be used in various environments to eradicate or control such bacteria.
Type:
Grant
Filed:
September 2, 1982
Date of Patent:
September 25, 1984
Assignee:
The Upjohn Company
Inventors:
Lester A. Dolak, Fritz Reusser, Thomas M. Castle, Betty R. Hannon, Alice L. Laborde, Charles K. Marschke
Abstract: Ethanol is produced by culturing the microorganism Kluyveromyces cellobiovorus or Kloeckera apiculata in a medium containing, as a carbon source, an assimilable source of xylose, cellobiose or both. The carbon source may be provided in the form of hydrolysates of cellulose containing substances such as cotton, wood, straw or paper which are obtained by acid hydrolysis or enzymatic action. At the completion of culturing, ethanol is removed from the culture in a conventional manner.
Abstract: A rat myeloma cell line which does not express an immunoglobulin chain, YB2/3.0.Ag.20, is prepared from the cell line Y3-Ag 1.2.3 via a hybrid myeloma cell line. This cell line, and variants thereof prepared by passaging and/or cloning the line, may be fused with immunocyte cells from an animal sensitized to an immunogen to produce hybrid myeloma cell lines which provide a source of monoclonal antibodies to said immunogen.
Type:
Grant
Filed:
July 7, 1981
Date of Patent:
September 18, 1984
Assignee:
National Research Development Corporation
Abstract: Method and compositions are provided for replication and expression of exogenous genes in microorganisms. Plasmids or virus DNA are cleaved to provide linear DNA having ligatable termini, which are bound to a gene having complementary termini, to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a microorganism cell by transformation. Isolation of the transformants provides cells for replication and expression of the DNA molecules present in the modified plasmid. The method provides a convenient and efficient way to introduce genetic capability into microorganisms for the production of nucleic acids are proteins, such as medically or commercially useful enzymes, which may have direct usefulness, or may find expression in the production of drugs, such as hormones, antibiotics, or the like, fixation of nitrogen, fermentation, utilization of specific feedstocks, or the like.
Type:
Grant
Filed:
November 9, 1978
Date of Patent:
August 28, 1984
Assignee:
The Board of Trustees of The Leland Stanford Junior University
Abstract: Longer carbon chain polyprenyl ketone derivatives are prepared by cultivag Nocardia strain FERM-P No. 1609 in the presence of shorter carbon chain polyprenyl ketones.
Type:
Grant
Filed:
December 3, 1982
Date of Patent:
August 28, 1984
Assignees:
Eisai Co., Ltd., Director General of the Agency of Industrial Science and Technology
Abstract: The present invention provides antisera and monoclonal antibodies directed against the sporozoite stage of the malaria parasite capable of providing protection against infection in both animals and humans. The invention further provides a purified antigen derived from sporozoites of the malaria parasite, the antigen being suitable for use as a vaccine against malarial infections in both animals and humans. The invention further provides means for preparing said antigen and a vaccine comprising said antigen.
Type:
Grant
Filed:
February 12, 1981
Date of Patent:
August 21, 1984
Assignee:
New York University
Inventors:
Ruth S. Nussenzweig, G. Nigel Godson, Victor Nussenzweig
Abstract: D-lactic acid is obtained by fermentation of a nutritive medium containing glucose and/or lactose and other usual additives by means of Lactobacillus bulgaricus DSM 2129.
Abstract: A novel antitumor antibiotic designated herein as BBM-2040 is produced by fermentation of Streptomyces sp. strain J576-99 (ATCC 39143). BBM-2040, which may be recovered from the fermentation broth in either a desmethanol (BBM-2040B) or methanol-adduct (BBM-2040A) form, inhibits gram-positive and acid-fast bacteria and inhibits the growth of tumors such as P388 leukemia in mice.
Abstract: Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.
Type:
Grant
Filed:
August 16, 1982
Date of Patent:
July 24, 1984
Assignee:
Bristol-Myers Company
Inventors:
James A. Matson, Robert W. Myllymaki, Terrence W. Doyle, James A. Bush
Abstract: Essentially pure plasmids derived from Actinomycetes are described which have at least one restriction cleavage site for specific restriction enzyme and have molecular weight of less than 1.0.times.10.sup.7.